pramipexole has been researched along with alpha-ergocryptine in 1 studies
| Studies (pramipexole) | Trials (pramipexole) | Recent Studies (post-2010) (pramipexole) | Studies (alpha-ergocryptine) | Trials (alpha-ergocryptine) | Recent Studies (post-2010) (alpha-ergocryptine) |
|---|---|---|---|---|---|
| 1,103 | 219 | 517 | 74 | 1 | 8 |
| Protein | Taxonomy | pramipexole (IC50) | alpha-ergocryptine (IC50) |
|---|---|---|---|
| 5-hydroxytryptamine receptor 4 | Cavia porcellus (domestic guinea pig) | 0.147 | |
| Cytochrome P450 3A4 | Homo sapiens (human) | 0.6 | |
| Alpha-2A adrenergic receptor | Homo sapiens (human) | 0.0079 | |
| Cytochrome P450 2C9 | Homo sapiens (human) | 6 | |
| Beta-3 adrenergic receptor | Homo sapiens (human) | 2.496 | |
| D(2) dopamine receptor | Homo sapiens (human) | 0.0019 | |
| Alpha-2B adrenergic receptor | Homo sapiens (human) | 0.026 | |
| Alpha-2C adrenergic receptor | Homo sapiens (human) | 0.038 | |
| 5-hydroxytryptamine receptor 1A | Rattus norvegicus (Norway rat) | 0.0026 | |
| D(1A) dopamine receptor | Homo sapiens (human) | 0.403 | |
| Alpha-1D adrenergic receptor | Homo sapiens (human) | 0.048 | |
| 5-hydroxytryptamine receptor 2A | Homo sapiens (human) | 0.047 | |
| 5-hydroxytryptamine receptor 2C | Homo sapiens (human) | 0.147 | |
| 5-hydroxytryptamine receptor 1B | Rattus norvegicus (Norway rat) | 0.0026 | |
| Mu-type opioid receptor | Homo sapiens (human) | 2.427 | |
| D(3) dopamine receptor | Homo sapiens (human) | 0.0006 | |
| 5-hydroxytryptamine receptor 2B | Homo sapiens (human) | 0.013 | |
| 5-hydroxytryptamine receptor 6 | Homo sapiens (human) | 0.016 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Groenke, L; Mueller, D; Oechsner, M | 1 |
1 other study(ies) available for pramipexole and alpha-ergocryptine
| Article | Year |
|---|---|
Pleural fibrosis associated with dihydroergocryptine treatment.
Topics: Aged; Antiparkinson Agents; Benzothiazoles; Cough; Dopamine Agonists; Dyspnea; Ergolines; Humans; Male; Parkinson Disease; Pramipexole; Pulmonary Fibrosis; Thiazoles | 2000 |